ProKidney Corp.

NASDAQ: PROK · Real-Time Price · USD
2.48
0.06 (2.48%)
At close: Aug 15, 2025, 12:11 PM

Company Description

ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates.

It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract.

The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

ProKidney Corp.
ProKidney Corp. logo
Country United States
IPO Date Jun 30, 2021
Industry Biotechnology
Sector Healthcare
Employees 204
CEO Bruce Culleton

Contact Details

Address:
2000 Frontis Plaza Blvd.
Winston-Salem, North Carolina
United States
Website https://www.prokidney.com

Stock Details

Ticker Symbol PROK
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001850270
CUSIP Number 74291D104
ISIN Number US74291D1046
Employer ID 98-1586514
SIC Code 2836

Key Executives

Name Position
Dr. Bruce Culleton M.D. Chief Executive Officer & Director
Carla Poulson Chief People Officer
James Coulston CPA Chief Financial Officer
Richard Williams Chief Information Officer
Todd C. Girolamo Esq., J.D., M.B.A. Chief Legal Officer & Secretary
Anu Biswas Senior Vice President of Manufacturing & Operations
Dr. Darin J. Weber Ph.D. Chief Reg. Off, SVice President and Head of Global Reg. Affairs, Quality Mgmt, Biometrics & Market Access
Dr. Joseph M. Stavas M.D., M.P.H. SVice President of Clinical Affairs
Dr. Ulrich Ernst Ph.D. EVice President of Science and Technology
Nikhil L. Pereira-Kamath Chief Business Officer

Latest SEC Filings

Date Type Title
Aug 12, 2025 8-K Current Report
Aug 12, 2025 10-Q Quarterly Report
Aug 07, 2025 SCHEDULE 13G/A [Amend] Filing
Jul 17, 2025 SCHEDULE 13G/A [Amend] Filing
Jul 16, 2025 8-K12B/A [Amend] Filing
Jul 15, 2025 8-K Current Report
Jul 14, 2025 8-K Current Report
Jul 14, 2025 424B5 Filing
Jul 11, 2025 4 Filing
Jul 09, 2025 4 Filing